Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulisokibart versus placebo in moderate to severe hidradenitis suppurativa
NL-OMON60904Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in hidradenitis suppurativa (HS) comparing Tulisokibart with Placebo (2 arms). Primary endpoint: Percentage of participants achieving HiSCR50 at Week 16. Started Sep 2025; status: active, not recruiting.
02
Drugs
tulisokibart
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON60904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60904.